Announcement on the Approval of Clinical Trial Notification for Innovative Drug APH03867 Tablets by Wholly-Owned Subsidiary

ApicHope Pharmaceutical Group Co., Ltd.·August 21, 2026·2 pages

✨ AI Summary

Yibaihong Pharmaceutical Group's wholly-owned subsidiary has received approval from the NMPA for the clinical trial of its innovative drug APH03867 tablets. The drug is intended for the treatment of gout with hyperuricemia. While the approval does not significantly impact the company's short-term financials, the drug development process is high-risk and long-term.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 300723

Securities Abbreviation: Yibaihong

Announcement Number: 2026-051

Yibaihong Pharmaceutical Group Co., Ltd.

Announcement on the Approval of Clinical Trial Notification for Innovative Drug APH03867 Tablets by Wholly-Owned Subsidiary

The Company and the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and do not contain any false records, misleading statements, or major omissions.

Recently, Yibaihong Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") received the "Drug Clinical Trial Approval Notification" from the National Medical Products Administration for the drug clinical trial application of its innovative drug APH03867 tablets, independently developed by its wholly-owned subsidiary Guangzhou Yibaihong Pharmaceutical Co., Ltd. The clinical trial will commence soon. The relevant situation is hereby announced as follows:

I. Main Content of the "Drug Clinical Trial Approval Notification"

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.